IONS

Ionis Pharmaceuticals Inc

Jul 16 • 04:00PM ET

42.77

Dollar change +0.77
Percentage change 1.83	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN VRTX GILD NBIX ALNY PRTA ARWR SRPT FOLD

| Held by: VTI VB VXF VBK XBI IBB IWP ARKG SCHA IWF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.98	Insider Own	2.44%	Shs Outstand	159.04M	Perf Week	-0.14%
Market Cap	6.81B	Forward P/E	-	EPS next Y	-3.17	Insider Trans	-3.79%	Shs Float	155.28M	Perf Month	20.17%
Enterprise Value	6.62B	PEG	-	EPS next Q	-0.24	Inst Own	104.21%	Short Float	9.11%	Perf Quarter	49.13%
Income	-457.68M	P/S	9.49	EPS this Y	-3.42%	Inst Trans	4.70%	Short Ratio	8.35	Perf Half Y	22.41%
Sales	717.68M	P/B	14.30	EPS next Y	-0.93%	ROA	-16.41%	Short Interest	14.14M	Perf YTD	22.34%
Book/sh	2.99	P/C	3.17	EPS next 5Y	22.47%	ROE	-118.53%	52W High	52.34 -18.28%	Perf Year	-10.90%
Cash/sh	13.50	P/FCF	-	EPS past 3/5Y	-146.45% -	ROIC	-18.90%	52W Low	23.95 78.58%	Perf 3Y	17.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-4.53% -8.88%	Gross Margin	95.48%	Volatility	3.49% 3.47%	Perf 5Y	-29.24%
Dividend TTM	-	EV/Sales	9.22	EPS Y/Y TTM	-11.81%	Oper. Margin	-65.71%	ATR (14)	1.37	Perf 10Y	-22.74%
Dividend Ex-Date	-	Quick Ratio	9.62	Sales Y/Y TTM	-7.65%	Profit Margin	-63.77%	RSI (14)	65.88	Recom	1.72
Dividend Gr. 3/5Y	- -	Current Ratio	9.66	EPS Q/Q	5.66%	SMA20	5.49%	Beta	0.24	Target Price	56.75
Payout	-	Debt/Eq	4.12	Sales Q/Q	10.14%	SMA50	16.77%	Rel Volume	0.82	Prev Close	42.00
Employees	1069	LT Debt/Eq	4.09	Earnings	Apr 30 BMO	SMA200	22.69%	Avg Volume	1.69M	Price	42.77
IPO	May 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.29% 0.46%	Trades		Volume	1,384,394	Change	1.83%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-25	Upgrade	Barclays	Equal Weight → Overweight	$57
Apr-07-25	Initiated	H.C. Wainwright	Buy	$45
Mar-31-25	Initiated	Redburn Atlantic	Neutral	$39
Aug-02-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$67 → $60
Jul-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$53 → $62
Jul-16-24	Resumed	Jefferies	Buy	$29 → $75
Jun-14-24	Upgrade	Bernstein	Underperform → Mkt Perform	$44
Apr-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$58
Jan-02-24	Upgrade	BofA Securities	Neutral → Buy	$52 → $62
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral	$33 → $52
Sep-29-23	Initiated	Raymond James	Strong Buy	$63
Jul-31-23	Upgrade	Citigroup	Neutral → Buy	$36 → $60
Jun-07-23	Resumed	Piper Sandler	Overweight	$58
May-04-23	Upgrade	Citigroup	Sell → Neutral	$30 → $36
Mar-21-23	Initiated	Bernstein	Underperform	$31
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $40
Sep-09-22	Resumed	Morgan Stanley	Overweight	$57
Jul-18-22	Resumed	Oppenheimer	Outperform	$59
Mar-31-22	Resumed	Piper Sandler	Overweight	$54
Mar-01-22	Initiated	Guggenheim	Buy	$64

Show Previous Ratings

Today 07:05AM	Ionis to hold second quarter 2025 financial results webcast (Business Wire)
Jul-14-25 04:01AM	Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035 \| Increase in Clinical Trials and Investments will Accelerate the Development of Innovative Treatments (GlobeNewswire)
Jul-10-25 12:39AM	Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT (Insider Monkey)
Jul-03-25 09:55AM	Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross? (Zacks)
08:17AM	Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? (Zacks)
07:11PM	Loading…
Jul-02-25 07:11PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research) +9.14%
09:36AM	Nike upgraded, Sportradar initiated: Wall Streets top analyst calls (TipRanks)
Jul-01-25 09:33AM	Nike upgraded, Sportradar initiated: Wall Street's top analyst calls (The Fly)
Jun-27-25 10:00AM	New Data for Nusinersen Underscore Biogens Commitment to Advancing Clinical Research to Improve Outcomes in SMA (GlobeNewswire)
Jun-25-25 04:19PM	Can Biogen Save Even More Kids With This New Drug? (Investor's Business Daily)
07:31AM	Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results (Business Wire)
07:30AM	Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? (Investor's Business Daily)
07:30AM	Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results (GlobeNewswire)
Jun-23-25 01:37AM	First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome (Insider Monkey)
Jun-12-25 09:00AM	Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 (Business Wire)
07:23AM	Loading…
07:23AM	Ionis doses first subject in Phase III trial of Angelman syndrome therapy (Clinical Trials Arena)
Jun-11-25 07:00AM	First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome (Business Wire)
Jun-05-25 11:30AM	Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? (Zacks)
Jun-04-25 11:30AM	Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue? (Zacks)
May-30-25 11:31AM	Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report? (Zacks)
May-22-25 12:43PM	Ionis reports success in olezarsen trial for high triglycerides (Clinical Trials Arena)
May-20-25 11:44AM	Ionis reports positive data from study of olezarsen for hypertriglyceridemia (Clinical Trials Arena)
08:58AM	Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study (Zacks)
May-19-25 07:00AM	Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides (Business Wire)
May-11-25 04:40PM	Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin's Stock Picks with Huge Upside Potential (Insider Monkey)
May-06-25 07:05AM	Ionis to host 2025 virtual Annual Meeting of Stockholders (Business Wire) -5.31%
May-02-25 07:25AM	Tweedy, Browne Fund Q1 2025 Commentary (Seeking Alpha)
May-01-25 01:37PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
10:42AM	Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View (Zacks)
09:35AM	ClearBridge Growth Portfolios Q1 2025 Commentary (Seeking Alpha)
09:30AM	Loading…
09:30AM	ClearBridge Growth ESG Portfolios Q1 2025 Commentary (Seeking Alpha)
03:16AM	Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
02:43AM	Q1 2025 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-30-25 09:35PM	ClearBridge Growth Fund Q1 2025 Commentary (Seeking Alpha)
02:20PM	Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:13AM	Ionis Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports first quarter 2025 financial results (Business Wire)
Apr-29-25 07:00AM	New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies (Business Wire)
Apr-25-25 10:00AM	Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-23-25 10:01AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-22-25 02:12PM	Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade) (Seeking Alpha)
Apr-18-25 04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-16-25 07:05AM	Ionis to hold first quarter 2025 financial results webcast (Business Wire)
Apr-10-25 08:20AM	Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains? (Zacks)
08:19AM	ClearBridge Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-03-25 10:48AM	BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag (Zacks)
07:05AM	Ionis to host expert panel discussion on sHTG (Business Wire)
Mar-31-25 07:05AM	Ionis to present at upcoming investor conferences (Business Wire)
Mar-28-25 11:30AM	Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? (Zacks)
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-27-25 11:32AM	Ionis and Sobi agree on olezarsen commercialisation (Pharmaceutical Technology)
08:31AM	IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi (Zacks)
Mar-26-25 07:00AM	Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. (Business Wire)
Mar-25-25 05:42PM	Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-24-25 08:00AM	Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire)
Mar-21-25 11:30AM	Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report? (Zacks)
Mar-12-25 01:46PM	Ono earmarks $940m to gain rare blood cancer therapy from Ionis (Pharmaceutical Technology)
09:56AM	Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal (Benzinga)
07:12AM	Ono pays $280M to license Ionis rare disease drug (BioPharma Dive)
Mar-11-25 06:00PM	Ionis and Ono announce global license agreement for sapablursen in polycythemia vera (Business Wire)
Mar-10-25 07:00AM	WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy (Business Wire)
Feb-27-25 02:09AM	Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ... (GuruFocus.com)
Feb-25-25 07:05AM	Ionis to present at upcoming investor conferences (Business Wire)
Feb-21-25 09:35AM	Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James (TipRanks)
Feb-20-25 12:14PM	Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now (Insider Monkey)
10:31AM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
07:00AM	New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control (Business Wire)
04:16AM	Q4 2024 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:10AM	Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com)
Feb-19-25 12:11PM	Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales (Benzinga)
09:30AM	Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:10AM	Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:19AM	Ionis Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports fourth quarter and full year 2024 financial results (Business Wire)
Feb-18-25 04:08PM	Ionis Pharmaceuticals (IONS): Among Top Insider Stock Buys And Sells In January (Insider Monkey)
Feb-17-25 09:16AM	Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS (Zacks)
Feb-12-25 10:00AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-11-25 01:59PM	Why Insiders Are Selling Ionis Pharmaceuticals, Inc. (IONS) Recently (Insider Monkey)
Feb-08-25 09:28AM	Why Ionis Pharmaceuticals, Inc. (IONS) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-05-25 07:05AM	Ionis to hold fourth quarter and full year 2024 financial results webcast (Business Wire)
Jan-23-25 07:30AM	FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA (GlobeNewswire) +6.03%
Jan-17-25 11:22AM	Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-15-25 09:17AM	Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034 (GlobeNewswire)
Jan-13-25 08:00AM	Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum (PR Newswire)
Jan-12-25 09:00PM	Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities (GlobeNewswire)
Jan-08-25 04:11PM	Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-20-24 07:44PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
03:09PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
10:23AM	FDA approves Ionis TRYNGOLZA for FCS treatment (Pharmaceutical Technology)
07:24AM	FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood (Benzinga)
06:00AM	Ionis gets a milestone approval; Another top FDA official to step down (BioPharma Dive)
Dec-19-24 06:28PM	TRYNGOLZA (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet (PR Newswire)
Dec-11-24 09:55AM	How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91% (Zacks)
Dec-08-24 05:55PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Dec-06-24 11:31AM	Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-05-24 07:35AM	Theratechnologies enters exclusive licensing agreement with Ionis (TipRanks)
Nov-27-24 12:00PM	Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Nov-26-24 08:00AM	Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting (GlobeNewswire)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Monia Brett P	Chief Executive Officer	Jul 11 '25	Sale	41.74	1,160	48,416	179,820	Jul 15 08:54 PM
Hayden Michael R	Director	May 01 '25	Buy	31.86	15,000	477,900	50,219	May 02 04:38 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 15 '25	Option Exercise	0.00	1,875	0	57,340	Apr 17 04:53 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 16 '25	Sale	28.37	680	19,292	56,660	Apr 17 04:53 PM
Jenne Kyle	EVP, Chf GL Pdt Str Ofcr	Apr 15 '25	Option Exercise	0.00	12,226	0	14,215	Apr 17 04:53 PM
Jenne Kyle	EVP, Chf GL Pdt Str Ofcr	Apr 16 '25	Sale	28.36	3,016	85,534	11,199	Apr 17 04:53 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 15 '25	Option Exercise	0.00	10,837	0	35,854	Apr 17 04:53 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 16 '25	Sale	28.40	3,928	111,555	31,926	Apr 17 04:53 PM
Jenne Kyle	Officer	Apr 16 '25	Proposed Sale	28.36	3,016	85,534		Apr 16 05:41 PM
Birchler Brian	Officer	Apr 16 '25	Proposed Sale	28.37	680	19,292		Apr 16 05:40 PM
Baroldi Joseph	Officer	Apr 16 '25	Proposed Sale	28.40	3,928	111,573		Apr 16 05:38 PM
Monia Brett P	Chief Executive Officer	Mar 11 '25	Sale	32.32	140	4,525	180,980	Mar 13 04:45 PM
Monia Brett P	Officer	Mar 11 '25	Proposed Sale	32.32	140	4,525		Mar 11 04:04 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Feb 20 '25	Sale	32.35	1,207	39,046	56,245	Feb 24 04:55 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Feb 04 '25	Sale	31.62	6,165	194,939	57,452	Feb 06 06:27 PM
Monia Brett P	Chief Executive Officer	Feb 04 '25	Sale	31.65	38,843	1,229,463	180,683	Feb 06 06:26 PM
Monia Brett P	Officer	Feb 04 '25	Proposed Sale	32.13	40,003	1,285,296		Feb 04 04:56 PM
O'NEIL PATRICK R.	Officer	Feb 04 '25	Proposed Sale	32.13	7,372	236,862		Feb 04 04:45 PM
Swayze Eric	EVP Research	Jan 31 '25	Sale	32.31	1,367	44,162	48,017	Feb 03 07:27 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 31 '25	Sale	32.20	1,484	47,780	61,056	Feb 03 07:27 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 31 '25	Sale	32.49	1,406	45,685	63,617	Feb 03 07:27 PM
Monia Brett P	Chief Executive Officer	Jan 31 '25	Sale	32.45	13,242	429,655	219,526	Feb 03 07:26 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 31 '25	Sale	32.44	1,523	49,404	110,500	Feb 03 07:26 PM
Geary Richard S	EVP, Chief Development Officer	Jan 31 '25	Sale	32.40	1,406	45,561	99,077	Feb 03 07:26 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 31 '25	Sale	32.46	1,327	43,079	93,146	Feb 03 07:26 PM
Schneider Eugene	Officer	Jan 31 '25	Proposed Sale	33.00	1,700	56,100		Jan 31 05:43 PM
Geary Richard S	Officer	Jan 31 '25	Proposed Sale	35.00	1,910	66,850		Jan 31 05:41 PM
Swayze Eric	Officer	Jan 31 '25	Proposed Sale	35.00	1,857	64,995		Jan 31 05:03 PM
O'NEIL PATRICK R.	Officer	Jan 31 '25	Proposed Sale	35.00	1,910	66,850		Jan 31 05:02 PM
HOUGEN ELIZABETH L	Officer	Jan 31 '25	Proposed Sale	35.00	2,069	72,415		Jan 31 05:01 PM
BENNETT C FRANK	Officer	Jan 31 '25	Proposed Sale	35.00	1,803	63,105		Jan 31 04:59 PM
Monia Brett P	Officer	Jan 31 '25	Proposed Sale	33.53	13,242	444,010		Jan 31 04:58 PM
YANG MICHAEL J.	Director	Jan 15 '25	Option Exercise	0.00	1,931	0	1,931	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 15 '25	Option Exercise	0.00	49	0	206	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 15 '25	Option Exercise	0.00	19,111	0	52,824	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 16 '25	Sale	32.84	7,154	234,959	45,670	Jan 17 07:41 PM
Swayze Eric	EVP Research	Jan 16 '25	Sale	32.70	22	719	184	Jan 17 07:41 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 15 '25	Option Exercise	0.00	17,372	0	65,031	Jan 17 07:41 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 16 '25	Sale	32.79	6,523	213,889	58,508	Jan 17 07:41 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 15 '25	Option Exercise	0.00	19,690	0	68,563	Jan 17 07:41 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 16 '25	Sale	32.83	7,360	241,629	61,203	Jan 17 07:41 PM
Monia Brett P	Chief Executive Officer	Jan 15 '25	Option Exercise	0.00	73,448	0	240,841	Jan 17 07:41 PM
Monia Brett P	Chief Executive Officer	Jan 16 '25	Sale	32.63	33,445	1,091,444	207,396	Jan 17 07:41 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 15 '25	Option Exercise	0.00	23,887	0	116,755	Jan 17 07:40 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 16 '25	Sale	32.81	8,870	290,989	107,885	Jan 17 07:40 PM
Geary Richard S	EVP, Chief Development Officer	Jan 15 '25	Option Exercise	0.00	18,901	0	103,735	Jan 17 07:40 PM
Geary Richard S	EVP, Chief Development Officer	Jan 16 '25	Sale	32.86	7,072	232,407	96,663	Jan 17 07:40 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 15 '25	Option Exercise	0.00	12,295	0	20,204	Jan 17 07:40 PM
Devers Shannon L.	EVP, Chief Human Resources Ofc	Jan 16 '25	Sale	32.78	4,267	139,855	15,937	Jan 17 07:40 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 15 '25	Option Exercise	0.00	14,283	0	60,451	Jan 17 07:40 PM
Birchler Brian	EVP, Corp and Development Ops	Jan 16 '25	Sale	32.70	5,400	176,580	55,051	Jan 17 07:40 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 15 '25	Option Exercise	0.00	18,011	0	97,618	Jan 17 07:40 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 16 '25	Sale	32.90	6,752	222,114	90,866	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 15 '25	Option Exercise	0.00	2,460	0	4,100	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 15 '25	Option Exercise	0.00	8,787	0	28,418	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '25	Sale	32.70	3,401	111,213	25,017	Jan 17 07:40 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 16 '25	Sale	32.70	1,029	33,648	3,071	Jan 17 07:40 PM
Swayze Eric	Officer	Jan 16 '25	Proposed Sale	32.70	7,154	233,936		Jan 16 07:31 PM
Schneider Eugene	Officer	Jan 16 '25	Proposed Sale	32.70	6,523	213,302		Jan 16 07:30 PM
O'NEIL PATRICK R.	Officer	Jan 16 '25	Proposed Sale	32.70	7,360	240,672		Jan 16 07:29 PM
Monia Brett P	Officer	Jan 16 '25	Proposed Sale	32.70	33,445	1,093,652		Jan 16 07:28 PM
HOUGEN ELIZABETH L	Officer	Jan 16 '25	Proposed Sale	32.70	8,870	290,049		Jan 16 07:25 PM
Geary Richard S	Officer	Jan 16 '25	Proposed Sale	32.70	7,072	231,254		Jan 16 07:23 PM
Devers Shannon L.	Officer	Jan 16 '25	Proposed Sale	32.70	4,267	139,531		Jan 16 07:22 PM
Birchler Brian	Officer	Jan 16 '25	Proposed Sale	32.70	5,400	176,580		Jan 16 07:21 PM
BENNETT C FRANK	Officer	Jan 16 '25	Proposed Sale	32.70	6,752	220,790		Jan 16 07:19 PM
Baroldi Joseph	Officer	Jan 16 '25	Proposed Sale	32.70	3,401	111,213		Jan 16 07:18 PM
Hayden Michael R	Director	Dec 23 '24	Buy	36.22	5,000	181,079	35,219	Dec 26 04:57 PM
Swayze Eric	EVP Research	Nov 12 '24	Sale	37.92	1,194	45,278	33,713	Nov 14 05:30 PM
Monia Brett P	Chief Executive Officer	Nov 12 '24	Sale	38.05	6,630	252,294	167,393	Nov 14 05:30 PM
LOSCALZO JOSEPH	Director	Nov 12 '24	Sale	37.86	13,508	511,426	32,251	Nov 14 05:30 PM
Monia Brett P	Officer	Nov 12 '24	Proposed Sale	38.89	6,629	257,774		Nov 12 04:17 PM
Swayze Eric	Officer	Nov 12 '24	Proposed Sale	38.88	1,194	46,422		Nov 12 04:16 PM
LOSCALZO JOSEPH	Officer	Nov 12 '24	Proposed Sale	38.88	13,508	525,152		Nov 12 04:15 PM
Swayze Eric	EVP Research	Oct 15 '24	Option Exercise	0.00	125	0	210	Oct 17 06:42 PM
Swayze Eric	EVP Research	Oct 16 '24	Sale	38.31	53	2,031	157	Oct 17 06:42 PM
Geary Richard S	EVP, Chief Development Officer	Aug 29 '24	Sale	49.63	331	16,428	84,823	Sep 03 07:18 PM
Geary Richard S	EVP, Chief Development Officer	Aug 28 '24	Sale	49.16	320	15,731	85,154	Sep 03 07:18 PM
Geary Richard S	EVP, Chief Development Officer	Aug 05 '24	Sale	48.00	2,430	116,640	85,508	Aug 06 05:27 PM
Geary Richard S	Executive Vice President, Chie	Aug 05 '24	Proposed Sale	49.13	3,128	153,678		Aug 05 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IONS

Ionis Pharmaceuticals Inc

Upgrade your FINVIZ experience